Trafalgar International (GCAN) Non Operating Income (2018 - 2025)
Trafalgar International (GCAN) posted Non Operating Income of $391563.0 for Q4 2025, up 29722.01% on a QoQ basis from $1313.0 in Q3 2025, and up 6941.92% year-over-year from $5560.5 in Q4 2024.
Powered by 
Analysis
Trafalgar International (GCAN) Non Operating Income (2018 - 2025) Analysis & Trends
Trafalgar International has reported Non Operating Income for 8 years, with the latest figure at $391563.0 in Q4 2025.
- On a quarterly basis, Non Operating Income rose 6941.92% year-over-year to $391563.0 in Q4 2025; TTM through Dec 2025 was -$9701.0, a 57.39% increase from a year earlier, with the FY2025 full-year figure at -$148607.0, down 552.79% from the prior year.
- Non Operating Income was $391563.0 for Q4 2025 at Trafalgar International, up from $1313.0 in the prior quarter.
- The five-year high for Non Operating Income was $391563.0 in Q4 2025, with the low at -$342602.0 in Q2 2025.
- Average Non Operating Income over 5 years is -$24390.8, with a median of -$5691.0 recorded in 2024.
- The largest YoY upside for Non Operating Income was 6941.92% in 2025 against a maximum downside of 5953.04% in 2025.
- Over 5 years, Non Operating Income stood at -$76229.0 in 2021, then surged by 93.27% to -$5134.0 in 2022, then soared by 44.8% to -$2834.0 in 2023, then tumbled by 101.94% to -$5723.0 in 2024, then jumped by 6941.92% to $391563.0 in 2025.
- The last three Non Operating Income figures came in at $391563.0 (Q4 2025), $1313.0 (Q3 2025), and -$342602.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | -139.24 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 41.90 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 391,563.00 |
| Sep 30, 2025 | 1,313.00 |
| Jun 30, 2025 | -342,602.00 |
| Mar 31, 2025 | -59,975.00 |
| Dec 31, 2024 | -5,723.00 |
| Sep 30, 2024 | -5,722.00 |
| Jun 30, 2024 | -5,660.00 |
| Mar 31, 2024 | -5,660.00 |
| Dec 31, 2023 | -2,834.00 |
| Sep 30, 2023 | -2,965.00 |
| Jun 30, 2023 | -3,639.00 |
| Mar 31, 2023 | -3,600.00 |
| Dec 31, 2022 | -5,134.00 |
| Sep 30, 2022 | -53,472.00 |
| Jun 30, 2022 | -19,371.00 |
| Mar 31, 2022 | -105,256.00 |
| Dec 31, 2021 | -76,229.00 |
| Sep 30, 2021 | -177,940.00 |
| Jun 30, 2021 | 23,510.00 |
| Mar 31, 2021 | -28,421.00 |